ScreenerHero

DRMADermata Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · dermatarx.com
1.420USD-3.40%Mkt Cap: 7.04M $P/E: —

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, incl…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap7.04M $
Enterprise Value1.14M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-7.56M $
Revenue/Share—
Last Price1.420 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees9
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.36
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.59
EPS (TTM)-3.94
EPS (Forward)-3.87
52W Range
0.95099% of range6.225
52W High6.225 USD
52W Low0.9509 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-121.45%
ROA-96.12%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.76M $
CapEx (TTM)—
FCF Margin—
FCF Yield-72.63%
Net Debt-4.41M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio2.81
Quick Ratio2.41
Book Value/Sh0.8670 USD
Cash/Share1.097 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateAug 1, 2025
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.000 USD
Upside (mean)+181.7%
Target Range4.000 USD – 4.000 USD
# Analysts1
Ownership
Shares Out.4.96M
Float3.17M
Insiders24.82%
Institutions7.77%
Short Interest
Short Ratio0.7d
Short % Float1.61%
Short % Out.1.26%
Shares Short50.76K
Short (prev mo.)131.49K
Technical
SMA 501.274 (+11.5%)
SMA 2001.692 (-16.1%)
Beta0.66
S&P 52W Chg18.16%
Avg Vol (30d)680.53K
Avg Vol (10d)4.23M
Technical Indicators
RSI (14)58.2
MACD0.0493
MACD Signal0.0130
MACD Hist.+0.0363
BB Upper1.567 USD
BB Middle1.258 USD
BB Lower0.9483 USD
BB Width49.18%
ATR (14)0.1411 USD
Vol Ratio (20d)0.23x